HeartBeam Secures $10M to Propel Remote Cardiac Care Revolution

SANTA CLARA, CA – April 16, 2026 – HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company poised to transform cardiac diagnostics, has successfully closed a $10 million public offering of common stock. The capital infusion is set to accelerate the commercial launch of its innovative, FDA-cleared cardiac monitoring platform and fuel further research and development into next-generation heart health technologies.

The offering, which involved the sale of 12,500,000 shares, was notably led by a consortium that signals deep-seated confidence in the company's trajectory. Participants included HeartBeam’s first commercial customer, ClearCardio™, alongside the company's executive leadership, board members, and a mix of existing and new institutional investors. This strategic financing provides HeartBeam with crucial capital as it transitions from a development-stage firm to a commercial entity in the competitive cardiac care market.

A Strategic Infusion Amid Market Volatility

The offering closed with shares priced at $0.80, a significant discount from the stock's price of $1.20 the day before the offering was announced. The timing comes as HeartBeam’s stock trades near its 52-week low, having experienced a notable decline year-to-date. This market performance underscores the challenging financial environment for pre-revenue med-tech companies.

However, the recent stock volatility stands in stark contrast to the bullish sentiment from market analysts. As of mid-April, multiple analysts held a “Strong Buy” consensus rating on HeartBeam, with price targets ranging from $4.00 to $8.00. This suggests a widespread belief on Wall Street that the company's underlying technology and long-term strategy are undervalued at current levels. The successful capital raise, despite market headwinds, provides the company with a critical financial runway.

Financial filings reveal the necessity of this funding. HeartBeam reported a net loss of $21.0 million for the full year 2025 and projects operating cash outflows of $17 million to $19 million for 2026. The company has been transparent about its cash burn as it invests heavily in R&D and prepares for its commercial debut. The $10 million in gross proceeds will be vital in supporting these operations as the company works toward its goal of achieving cash-flow breakeven, a milestone it estimates will occur upon enrolling approximately 30,000 patients into its subscription-based model.

Customer-Led Financing Signals Strong Market Validation

A powerful element of this offering is the leadership role taken by ClearCardio™, HeartBeam’s first commercial partner. ClearCardio™, a prominent preventive cardiology practice, caters to a premium, proactive patient base willing to invest in innovative health solutions. The practice entered into a commercial partnership with HeartBeam in March 2026 to integrate the company’s synthesized 12-lead ECG technology into its cardiac prevention programs.

By leading the financing round, ClearCardio™ has provided more than just capital; it has delivered a potent strategic endorsement. This move signals a strong belief from a key customer in the clinical utility and market-readiness of HeartBeam's technology. For potential investors and future customers, this action serves as powerful validation of the product-market fit and the viability of HeartBeam’s recurring revenue subscription model.

The partnership outlines an initial staged rollout designed to ensure a seamless experience for both patients and physicians, with plans for broader expansion. This collaboration is the first real-world test of HeartBeam’s commercial strategy, making ClearCardio’s subsequent financial commitment a significant vote of confidence.

Redefining Diagnostics Beyond the Clinic

At the core of HeartBeam's value proposition is its platform technology, designed to shift critical cardiac monitoring from the hospital to the home. The company has secured two key FDA clearances that form the foundation of its commercial strategy.

In December 2024, it received clearance for its core HeartBeam System, a portable, credit card-sized device that uses five electrodes to collect 3D ECG signals. This cable-free approach allows patients to capture a recording whenever symptoms occur, addressing the challenge of diagnosing intermittent arrhythmias that may not be present during a doctor's visit.

A year later, in December 2025, the company secured a pivotal 510(k) clearance for its 12-lead ECG synthesis software. This software uses the data from the 3-lead device to generate a synthesized 12-lead ECG view for arrhythmia assessment by a physician. While the output is not intended to replace a standard hospital 12-lead ECG, a pivotal study demonstrated a 93.4% diagnostic agreement for arrhythmia detection, highlighting its clinical potential.

HeartBeam is planning a limited market launch of the system in early 2026, targeting select concierge and preventive cardiology groups that have already expressed strong interest. This phased approach will allow the company to gather real-world data, establish reference sites, and refine its commercial model before a wider rollout.

Navigating a Competitive and Growing Market

HeartBeam is entering a dynamic and rapidly expanding market. The global cardiac monitoring sector was valued at over $26 billion in 2025 and is projected to exceed $43 billion by 2034. The shift towards remote patient monitoring and wearable technology is fueling this growth, creating a fertile but competitive landscape.

The company faces a host of well-funded competitors, including startups like Wearlinq, which recently raised $14 million for its 6-lead wireless monitor, and Cardiosense, which secured $15.1 million for its AI-driven wearable. Established players and other innovators like Kestra and AliveCor are also vying for market share in the remote and wearable ECG space.

HeartBeam aims to differentiate itself with its unique 3D vector ECG data capture. The company believes this richer dataset will not only provide immediate clinical insights but will also be instrumental in training superior AI algorithms for predictive cardiac analysis in the future. The net proceeds from the offering will be used to advance these AI capabilities, alongside other key pipeline initiatives.

These initiatives include the development of an extended-wear patch for on-demand monitoring and, most significantly, the pursuit of an indication for heart attack detection. A study published in JACC: Advances showed HeartBeam’s technology was comparable to a standard 12-lead ECG in identifying coronary occlusions, suggesting a major future application that could dramatically expand the company's impact and market opportunity. This latest funding round is a critical step toward realizing that ambitious vision.